About NuCana (NASDAQ:NCNA)
NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. The company was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-20.77
Forward P/E Ratio-23.73
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$3.78 per share
Price / Book5.96
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
NuCana (NASDAQ:NCNA) Frequently Asked Questions
What is NuCana's stock symbol?
NuCana trades on the NASDAQ under the ticker symbol "NCNA."
What price target have analysts set for NCNA?
4 equities research analysts have issued 1 year price targets for NuCana's stock. Their forecasts range from $23.00 to $25.00. On average, they anticipate NuCana's share price to reach $24.00 in the next year. View Analyst Ratings for NuCana.
Who are some of NuCana's key competitors?
Some companies that are related to NuCana include Tesaro (TSRO), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec A.G. (EVTCY), Ascendis Pharma (ASND), Clovis Oncology (CLVS), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA), Global Blood Therapeutics (GBT) and AnaptysBio (ANAB).
Who are NuCana's key executives?
NuCana's management team includes the folowing people:
- Prof. Christopher B. Wood Ph.D., M.D., FRCS, Chairman & Chief Medical Officer (Age 72)
- Mr. Hugh S. Griffith, CEO & Director (Age 50)
- Mr. Donald Munoz, CFO & Principal Accounting Officer (Age 49)
When did NuCana IPO?
(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.
When did NuCana's lock-up period expire?
NuCana's lock-up period expired on Tuesday, March 27th. NuCana had issued 6,667,000 shares in its IPO on September 28th. The total size of the offering was $100,005,000 based on an initial share price of $15.00. Since the expiration of NuCana's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Has NuCana been receiving favorable news coverage?
News stories about NCNA stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuCana earned a news sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the company an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of NuCana?
Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuCana's stock price today?
One share of NCNA stock can currently be purchased for approximately $22.54.
How big of a company is NuCana?
NuCana has a market capitalization of $731.34 million. The company earns $-29,750,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. NuCana employs 16 workers across the globe.
How can I contact NuCana?
NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1248-3660.
MarketBeat Community Rating for NuCana (NCNA)MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
NuCana (NASDAQ:NCNA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
NuCana (NASDAQ NCNA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 30.70%
NuCana (NASDAQ NCNA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
NuCana (NASDAQ NCNA) News Headlines
NuCana (NASDAQ:NCNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NuCana (NASDAQ:NCNA) Income Statement, Balance Sheet and Cash Flow Statement
NuCana (NASDAQ NCNA) Stock Chart for Wednesday, April, 25, 2018